DNA X, Inc. SONM
3.92
(0.03)
(0.76%)
as of 25 Sep
- Market cap
- $5.9M
- P/E
- 0.0×
Follow SONM
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
P/E ratio |
+8 more quarters Free account |
0.00 | — | — | — |
P/S ratio |
0.18 | — | — | — | |
P/FCF ratio |
0.00 | — | — | — | |
P/Operating CF |
(1.52) | — | — | — | |
P/B ratio |
0.00 | — | — | — | |
Price to Tangible BV |
0.00 | — | — | — | |
EV/Sales |
0.15 | — | — | — | |
EV/EBITDA |
0.18 | — | — | — | |
EV/Operating CF |
(0.34) | — | — | — | |
EV/FCF |
(0.34) | — | — | — | |
Quick Ratio |
0.40 | 0.03 | 0.62 | 0.42 | |
Current Ratio |
0.78 | 0.57 | 0.76 | 0.57 | |
Net Debt/EBITDA |
0.62 | (0.07) | 0.33 | 0.76 | |
Debt/Assets |
0.62% | 0.00% | 0.00% | 0.00% | |
Debt/Equity |
(0.36) | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
1.32 | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
1.48 | 0.23 | (0.55) | 1.60 | |
Capex/Depreciation |
0.00 | 0.00 | 78.09 | (1.03) | |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
1.12% | — | — | — | |
Selling, General and Administrative Expense of Revenue |
34.63% | 0.00% | 0.00% | 0.00% | |
Intangible Assets out of Total Assets |
0.23 | 0.00 | 0.00 | 0.31 | |
Share Based Compensation of Revenue |
1.02% | 0.00% | 0.00% | 0.00% | |
Graham Net Nets |
(0.99) | — | — | — | |
Graham Number |
39.91 | — | — | — | |
Earnings Yield |
(915.10%) | — | — | — | |
Free Cash Flow Yield |
(245.15%) | — | — | — | |
Revenue per Share |
16.46 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(7.14) | (2.77) | (2.74) | (1.48) | |
Capex per Share |
0.00 | 0.00 | 2.65 | (0.07) | |
Free Cash Flow per Share |
(7.14) | (2.77) | (0.09) | (1.55) | |
Cash per Share |
2.17 | 1.80 | 0.94 | 0.67 | |
Shareholders Equity per Share |
(0.71) | (11.01) | (0.78) | (0.91) | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
(0.71) | (11.01) | (0.78) | (0.91) | |
Free Cash Flow |
(7.03) | (2.00) | (0.11) | (2.09) | |
Working Capital |
(8.55) | (21.72) | (1.02) | (2.23) | |
Capital Expenditures |
— | — | 3.36 | (0.09) | |
Net Current Asset Value |
(10.62) | (22.94) | (2.52) | (2.83) | |
EV/EBIT |
4.20 | — | — | — | |
Capex to Sales |
0.00 | — | 0.00 | 0.00 | |
Net Profit Margin |
(29.31%) | 0.00% | 0.00% | 0.00% | |
Price to Operating Income |
0.24 | — | — | — | |
| Other line items | |||||
Average Receivables |
11.77 | — | 6.57 | 6.37 | |
Average Payables |
14.73 | 2.38 | 9.01 | 10.63 | |
Average Inventory |
11.68 | — | — | — | |
Average Assets |
44.68 | 41.82 | 20.40 | 20.30 | |
Average Common Equity |
7.32 | (6.83) | (1.03) | (1.28) |
Columns are period end dates